A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in
combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by
evaluation of the safety and efficacy of lucitanib and nivolumab in patients with an advanced
gynecological solid tumor (Phase 2) and evaluate the effects of dosing under fasting or fed
state (Food Effect)
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Clovis Oncology, Inc.
Collaborators:
Bristol-Myers Squibb European Network of Gynaecological Oncological Trial Groups (ENGOT)